Sai Life Sciences Ltd
Incorporated in 1999, Sai Life Sciences
Ltd carries out contract research and manufacturing activities for customers
engaged in pharmaceutical and bio
technology industries[1]
- Market Cap ₹ 18,277 Cr.
- Current Price ₹ 870
- High / Low ₹ 943 / 635
- Stock P/E 63.8
- Book Value ₹ 108
- Dividend Yield 0.00 %
- ROCE 14.0 %
- ROE 11.0 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is expected to give good quarter
Cons
- Stock is trading at 8.10 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 7.86% over last 3 years.
- Working capital days have increased from 37.8 days to 66.4 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 695 | 726 | 760 | 870 | 1,217 | 1,465 | 1,695 | 2,053 | |
| 520 | 558 | 593 | 743 | 1,048 | 1,178 | 1,285 | 1,509 | |
| Operating Profit | 176 | 168 | 167 | 126 | 169 | 287 | 410 | 544 |
| OPM % | 25% | 23% | 22% | 15% | 14% | 20% | 24% | 26% |
| 6 | 18 | 27 | 28 | 27 | 29 | 35 | 44 | |
| Interest | 24 | 22 | 33 | 54 | 81 | 88 | 78 | 56 |
| Depreciation | 44 | 55 | 80 | 90 | 99 | 119 | 139 | 149 |
| Profit before tax | 113 | 109 | 82 | 10 | 16 | 109 | 228 | 383 |
| Tax % | 35% | 30% | 25% | 36% | 39% | 24% | 25% | |
| 73 | 76 | 61 | 6 | 10 | 83 | 170 | 286 | |
| EPS in Rs | 8.16 | 13.73 | ||||||
| Dividend Payout % | 0% | 0% | 0% | 1,116% | 676% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 25% |
| TTM: | 37% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 229% |
| TTM: | 131% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 8% |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 17 | 18 | 18 | 18 | 21 | 21 |
| Reserves | 703 | 778 | 845 | 861 | 870 | 957 | 2,108 | 2,249 |
| 249 | 304 | 637 | 752 | 933 | 928 | 352 | 418 | |
| 247 | 312 | 318 | 527 | 358 | 359 | 665 | 644 | |
| Total Liabilities | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,332 |
| 373 | 641 | 701 | 751 | 1,037 | 1,180 | 1,488 | 1,622 | |
| CWIP | 116 | 91 | 246 | 410 | 151 | 107 | 124 | 115 |
| Investments | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 |
| 726 | 679 | 870 | 997 | 989 | 973 | 1,531 | 1,592 | |
| Total Assets | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,332 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 129 | 116 | -36 | 105 | 219 | 263 | 314 | |
| -158 | -262 | -260 | -102 | -99 | -191 | -536 | |
| 268 | -4 | 296 | 72 | -201 | -95 | 301 | |
| Net Cash Flow | 239 | -150 | -1 | 75 | -80 | -24 | 79 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 123 | 136 | 99 | 102 | 85 | 64 | 76 |
| Inventory Days | 86 | 79 | 127 | 179 | 121 | 72 | 93 |
| Days Payable | 207 | 258 | 230 | 279 | 180 | 113 | 253 |
| Cash Conversion Cycle | 1 | -43 | -4 | 2 | 25 | 22 | -83 |
| Working Capital Days | 55 | 24 | 62 | 42 | 36 | 12 | 66 |
| ROCE % | 13% | 9% | 3% | 6% | 11% | 14% |
Documents
Announcements
- Intimation For Order Dated 19Th November 2025 Issued By The Joint Commissioner Of Commercial Taxes (Appeals), Kalaburagi U/S 107 (11) Of The Karnataka Goods And Services Tax Act, 2017 And The Central Goods And Services Tax Act, 2017. 33s
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 14 Nov
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
13 Nov - Investor/analyst meetings rescheduled to Nov 19 (Morgan Stanley, Singapore) and Nov 20 (Annual Asia Pacific Summit).
-
Intimation Of Order Dated 12Th November, 2025 Passed By The Assistant Commissioner, Central Tax, Division-II (Pimpri), Pune-I Commissionerate U/S 74 Of The CGST Act, 2017.
13 Nov - Order (12 Nov 2025) by Assistant Commissioner CGST Pune: IGST demand INR 70,15,687; penalty INR 70,15,687; company will seek rectification.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
13 Nov - Investor Meeting intimation scheduled to be held on November 18-19, 2025, in Singapore.
Concalls
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Feb 2025TranscriptNotesPPT REC
Business Overview:[1]
a) SLS is a Hyderabad-based contract research development and manufacturing organisation in the pharmaceutical sector with a significant presence in regulatory markets of US and Europe.
b) It offers integrated services across the pharmaceutical lifecycle from discovery services to development and manufacturing of new chemical entities to global innovator pharmaceutical and biotechnology companies.
c) In FY24, company has completed
200+ discovery programmes and 40+ programmes have advanced to clinical
phases.
d) SLS has a fully integrated in-house
synthetic and medicinal chemistry, drug metabolism, biology, pharmacokinetics
and toxicology.
e) In terms of therapy, they have worked in oncology and other key therapy areas include central nervous system, inflammation and anti
virals.
f) SLS provides its services to 17 out of the top 20 global pharmaceutical companies and several biotechnology companies.